Immunic

NAQ:IMUX · US4525EP1011

BiotechnologySmall

360° View

Value8

Price/Sales—

Price/Earnings16

Price/Book56

Dividend Yield1

Growth34

Revenue Growth—

Profit Growth53

Capital Growth21

TSR 52w63

Safety60

Leverage97

Liquidity56

Refinancing1

Combined18

Sentiment93

Analyst Opinions100

Pro Holdings45

Opinion Changes96

Market Pulse39

Profile

CountryUSA

IndustryBiotechnology

SizeSmall

TypePublic Company

ExchangeNASDAQCM

Employees81

Websiteimux.com

ISINUS4525EP1011

Last UpdateApr 2, 2026

Index & Theme

Chronic DiseasesInflammationGastroenterologyImmunologyNeurologyObesityCentral Nervous SystemBiotechnologyLife ScienceMedicalTherapeutics

Description

Immunic, Inc. (Immunic) is a late-stage biotechnology company. The company is developing novel oral therapies for neurologic and gastrointestinal diseases. The company is pursuing clinical development of orally administered, small molecule programs…

Analysis

Immunic's 360° View rank of 38 places it below its peer average — better than 38% of its true peers.

It's growing slowly (34) and expensive versus peers (8). On safety it is financially sound (60), and the market shows strongly positive sentiment (93). Taken together, its Combined rank of 18 reads as among the weakest overall.

360° rank · history

1007550250

2026

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023

Price/Sales

—

Price/Earnings

—

Price/Book

—

Dividend Yield

—

Value (overall)

—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Immunic with its peers

Forte Biosciences

NAQ:FBRX

—

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Arcellx

NSQ:ACLX

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Dyne Therapeutics

NSQ:DYN

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Nurix Therapeutics

NMQ:NRIX

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Cabaletta Bio

NSQ:CABA

—

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Seres Therapeutics

NSQ:MCRB

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View

1 · Watch OutGood· 100

Value

1 · ExpensiveGood Value· 100

Quality

1 · Weak FundamentalsHigh Quality· 100

Growth

1 · Tough TimesHigh Growth· 100

Safety

1 · High LeverageWell-Financed· 100

Sentiment

1 · SkepticismPositive· 100

Learn More →